The effectiveness of dapagliflozin for sleep-disordered breathing among Japanese patients with obesity and type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Weight reduction is important in patients with sleep-disordered breathing (SDB). In Japanese patients, slight weight reduction is effective for improving the severity of SDB. However, the effect of weight reduction after administration of sodium glucose co-transporter 2 (SGLT2) inhibitor for SDB remains unclear. The aim of this study was to evaluate the improvement of SDB from baseline after administration of dapagliflozin (5 mg) once daily for 24 weeks among Japanese patients with obesity and type 2 diabetes mellitus. Thirty Japanese patients with type 2 diabetes mellitus and SDB were enrolled in a 24-week, prospective, open-label, single-arm, multicentre trial. SDB was defined as at least five 3% oxygen desaturation index (ODI) events per hour, and moderate to severe SDB was defined as at least 15 ODI events per hour. The primary endpoint was the change in 3% ODI between before dapagliflozin administration and at 24 weeks. The prevalence of moderate to severe SDB was 20% in the present study. After administration of dapagliflozin, fasting glucose, HbA1c, aspartate aminotransferase, total cholesterol, low-density lipoprotein cholesterol, and estimated globular filtration rate decreased significantly. The improvement of 3% ODI was observed in patients with moderate to severe SDB but not mild SDB (from 25.0 ± 3.8 at baseline to 18.5 ± 6.1 at 24 weeks, p = 0.017). In conclusion, dapagliflozin might improve moderate to severe SDB but not mild SDB in Japanese patients with obesity and type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Day–Night Pattern of Sudden Death in Obstructive Sleep Apnea
Gami, A. S., Howard, D. E., Olson, E. J., & Somers, V. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041832 · Cited by 1,032
Effects of Sleep Fragmentation on Glucose Metabolism in Normal Subjects
Stamatakis, K. A., & Punjabi, N. M. (2010) · Chest · doi:10.1378/chest.09-0791 · Cited by 614
Foster, G. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.266 · Cited by 538
β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
Yabe, D., Seino, Y., Fukushima, M., & Seino, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0602-9 · Cited by 328
Cited by
Pugliese, G., Barrea, L., Laudisio, D., Salzano, C., Aprano, S., Colao, A., Savastano, S., & Muscogiuri, G. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00369-y · Cited by 94
Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1096 · Cited by 93
“Indeed, a small, openlabel, single-arm study in Japanese patients with moderate to severe OSA, obesity, and diabetes showed improved metabolic parameters and less oxygen desaturation events with low-dose dapagliflozin administered over 24 weeks (30).”
BackgroundNew frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review
Schütz, S. G., Dunn, A., Braley, T. J., Pitt, B., & Shelgikar, A. V. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101473 · Cited by 47
Metadata
- Authors
- Furukawa, S., Miyake, T., Senba, H., Sakai, T., Furukawa, E., Yamamoto, S., Niiya, T., Matsuura, B., & Hiasa, Y.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2018
- Volume
- 65
- Issue
- 9
- Pages
- 953-961
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2883444112
- Cited by
- 44
- References
- 5
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.